Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Abhishek A. et al, (2025), Efficacy and mechanism evaluation, 1 - 42
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A. et al, (2024), Lancet rheumatol, 6, e92 - e104
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2023), Lancet rheumatology, 6, e92 - e104
How should we best measure participant-reported ‘average hand pain’: comparison of two methods from a randomized placebo-controlled feasibility study of post-menopausal women with hand osteoarthritis
Williams JA. et al, (2023), Osteoarthritis and cartilage, 31, s187 - s188
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.
Williams JAE. et al, (2022), Lancet rheumatol, 4, e725 - e737
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A. et al, (2022), Lancet respir med, 10, 840 - 850
Two-week interruption in methotrexate treatment versus treatment continued as usual and COVID-19 booster immunity in adults with inflammatory conditions (VROOM study): a randomised open label, superiority trial
Abhishek A. et al, (2022), The lancet respiratory medicine
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).
Abhishek A. et al, (2022), Bmj open, 12
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS. et al, (2016), Lancet oncol, 17, 1543 - 1557
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D. et al, (2015), Gut, 64, 111 - 120
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Dutton SJ. et al, (2014), Lancet oncol, 15, 894 - 904
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D. et al, (2014), J clin oncol, 32, 1031 - 1039
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S. et al, (2013), Journal of clinical oncology, 31, TPS5615 - TPS5615
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S. et al, (2013), Journal of clinical oncology, 31
Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG).
Dutton SJ. et al, (2013), Journal of clinical oncology, 31, 6 - 6
CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
Midgley RS. et al, (2012), Annals of oncology, 23, 181 - 182
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS. et al, (2010), J clin oncol, 28, 4575 - 4580
VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
Midgley RSJ. et al, (2008), Annals of oncology, 19, 1 - 1